Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...
Cognitive decline and dementia pose significant challenges to aging populations worldwide, but new research offers hope. A groundbreaking study suggests that cognitive "speed training" can reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results